Human Resources Manager

Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting! What You'll Do: Develop and implement HR strategies and initiatives that align with the organization's goals. Manage the recruitment and selection process, including job postings, interviews, and onboarding. Administer compensation and benefits programs, ensuring competitive and fair packages for employees. Provide support and guidance to managers and employees on HR-related issues, including employee relations, performance management, and disciplinary actions. Ensure compliance with employment laws, regulations, and company policies. Develop and update HR policies and procedures as needed. Coordinate employee training and development programs to enhance skills and performance. Foster a positive work environment and promote employee engagement and retention. Manage HR records and ensure data accuracy and confidentiality. Lead the HR team, providing direction, support, and professional development. Skills and Experience we look for: Proven experience as a Human Resources Manager or similar HR role. Comprehensive knowledge of employment laws, regulations, and HR best practices. Excellent leadership and interpersonal skills. Strong communication and problem-solving abilities. Experience in recruitment, employee relations, and performance management. Ability to work collaboratively with all levels of the organization. Strong organizational and time management skills. Proficiency in HR software and Microsoft Office Suite. Education: Professional certification such as PHR, SPHR, SHRM-CP, or SHRM-SCP is highly desirable. At least 2 years of experience in HR management or a related role is desired Experience in employee training and development is a plus About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non‑specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART‑2 (NCT06097832), with a registrational design. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and #J-18808-Ljbffr